Key Highlights

  • Loss per share was USD 0.53 against an estimate of a USD 0.47 loss.
  • Sales were USD 404.6 thousand against an estimate of USD 810 thousand.
  • Net loss was USD 4.56 million, compared with USD 4.19 million.
  • Cash and cash equivalents were USD 23.91 million at September 30.

Femasys (NASDAQ:FEMY) reported a third quarter 2026 loss per share of USD 0.53, against an estimate of a USD 0.47 loss. Sales were USD 404,597, against an estimate of USD 810 thousand and USD 729,394 in the third quarter of 2025. The net loss was USD 4,564,815, compared with USD 4,194,821.

The loss from operations was USD 4,450,010, compared with USD 3,653,768. The company reported the figures in its quarterly filing for the period ended September 30, 2026.

Operating Expenses

Cost of sales, excluding Depreciation expense, was USD 187,496, compared with USD 293,838. Research and Development expenses were USD 1,942,927, compared with USD 1,382,022, and sales and Marketing expenses were USD 943,002, compared with USD 1,143,805. General and administrative expenses were USD 1,704,091, compared with USD 1,477,800, and depreciation and amortization was USD 77,091, compared with USD 85,697.

Total operating expenses were USD 4,667,111, compared with USD 4,089,324. Interest income was USD 85,610, compared with USD 17,315.

Nine-Month Results

For the nine months ended September 30, 2026, sales were USD 1,161,313, compared with USD 1,479,926, and the loss from operations was USD 13,739,417, compared with USD 12,965,941. Total operating expenses were USD 14,412,192, compared with USD 13,876,592.

The net loss for the nine months was USD 8,187,810, compared with USD 14,677,582. The nine-month period included a USD 1,732,413 change in the Fair Value of a conversion option liability, and interest income was USD 155,131, compared with USD 53,488. Net cash used in Operating Activities was USD 12,896,701, compared with USD 14,505,325.

Balance Sheet

Cash and cash equivalents were USD 23,913,946, compared with USD 9,266,353 at the prior Balance Sheet date. Accounts receivable, net, were USD 233,778, compared with USD 616,600, and inventory was USD 6,166,371, compared with USD 5,740,249. Prepaid and other current Assets were USD 893,098, compared with USD 833,133.

Total assets were USD 35,087,658, compared with USD 20,724,177. Total share-based compensation expense was USD 190,216 for the quarter, compared with USD 174,514, and USD 552,644 for the nine months, compared with USD 723,722.

The filing states that, as of September 30, 2026, the company had cash and cash equivalents of USD 23,913,946, and that it believes this amount provides sufficient Liquidity to fund its planned operations, Capital requirements and other obligations for at least the twelve-month period following issuance of the financial statements. It also states that all share and per share information has been retroactively adjusted to reflect the 1-for-20 Reverse Stock Split for all periods presented.

Paid-in-kind interest and amortization of Debt issuance costs and discount on the 2023 and 2025 notes were USD 196,427 for the quarter, compared with USD 426,541. Share-based compensation in research and development was USD 33,630, compared with USD 65,625, in sales and marketing was USD 11,529, compared with USD 19,047, and in general and administrative was USD 145,057, compared with USD 89,842.

Femasys Q3 2026 Earnings: Key Takeaways

Femasys reported a third quarter 2026 loss per share of USD 0.53, sales of USD 404,597 and a net loss of USD 4,564,815. Cash and cash equivalents were USD 23,913,946 at September 30, 2026.